The primary concern with hepatic impairment is a potential change in exposure to a drug that is extensively cleared by hepatic metabolism or biliary excretion via the liver, that could impact on the pharmacodynamic action or lead to adverse effects [19]
The study is underpinned by the hypothesis that a high level of therapeutic success can be achieved in patients with IC using a combination of approaches
AOD-9604, a specialized fragment of human growth hormone, supports fat breakdown and helps block new fat storage without impacting blood sugar or IGF-1
It boosts the synthesis of collagen, elastin, glycosaminoglycans, and other structural proteins that maintain firmness and elasticity
It has attracted significant, sustained attention in in-vitro research focused intensely on connective tissue, skeletal muscle fibers, tendons, ligaments, and highly specialized gastrointestinal tissue models